…
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
CStone Pharmaceuticals is a China-based biopharmaceutical company focused on developing and commercializing oncology and immuno-oncology therapies, with multiple clinical-stage programs. Its long-term growth may benefit from progression of clinical programs, potential regulatory approvals, broader demand for cancer treatments in China and collaborations that could support development and market access.
Principal risks include clinical and regulatory setbacks, significant funding and execution requirements, intense competition from domestic and multinational oncology firms, and limited liquidity and disclosure constraints associated with a Pink-sheet listing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -413.00M | -91.21M | -367.23M | -902.68M | -1920.10M |
| Net income | -425.73M | -91.21M | -367.23M | -902.68M | -1920.10M |
| Selling general administrative | - | 33.16M | 48.72M | 63.17M | 109.20M |
| Selling and marketing expenses | - | 133.78M | 199.35M | 327.30M | 363.79M |
| Gross profit | 44.79M | 240.15M | 304.30M | 278.38M | 136.89M |
| Reconciled depreciation | - | 49.80M | 58.19M | 44.54M | 22.66M |
| Ebit | -421.46M | -76.04M | -355.42M | -832.27M | -1852.75M |
| Ebitda | -378.61M | -26.23M | -297.23M | -787.73M | -1830.09M |
| Depreciation and amortization | 42.85M | 49.80M | 58.19M | 44.54M | 22.66M |
| Operating income | -421.46M | -91.69M | -579.85M | -832.27M | -1852.75M |
| Other operating expenses | 684.08M | 498.90M | 1043.69M | 1384.87M | 2037.19M |
| Interest expense | 12.93M | 15.17M | 11.82M | 8.48M | 2.24M |
| Interest income | - | 12.67M | 24.89M | 9.67M | 9.80M |
| Net interest income | - | -2.50M | 13.07M | 1.20M | 7.56M |
| Income tax expense | 12.73M | - | 58.02M | - | - |
| Total revenue | 262.63M | 407.20M | 463.84M | 481.36M | 243.72M |
| Total operating expenses | 466.24M | 331.85M | 884.14M | 1181.89M | 1930.36M |
| Cost of revenue | 217.84M | 167.05M | 159.55M | 202.99M | 106.83M |
| Total other income expense net | 8.46M | 0.48M | 212.61M | -70.41M | -67.35M |
| Net income from continuing ops | - | -91.21M | -367.23M | -902.68M | -1920.10M |
| Net income applicable to common shares | - | - | - | - | -1920.10M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1359.05M | 1393.47M | 1662.00M | 1638.43M | 2271.45M |
| Intangible assets | - | 161.37M | 173.04M | 159.70M | 70.54M |
| Other current assets | 43.81M | - | 21.85M | - | - |
| Total liab | 667.49M | 1029.60M | 1205.17M | 1189.10M | 1064.44M |
| Total stockholder equity | 617.08M | 363.87M | 456.83M | 449.33M | 1207.01M |
| Other current liab | 231.17M | 248.99M | 446.99M | 611.15M | 855.98M |
| Common stock | 1.00M | 0.86M | 0.86M | 0.80M | 0.80M |
| Capital stock | - | 0.86M | 0.86M | 0.80M | 0.80M |
| Retained earnings | - | -9110.93M | -9019.73M | -8652.49M | -7749.81M |
| Other liab | - | - | - | - | 1.25M |
| Other assets | 0.00M | - | - | - | 57.28M |
| Cash | 754.08M | 387.94M | 996.67M | 558.68M | 742.72M |
| Total current liabilities | 510.48M | 682.01M | 850.34M | 946.48M | 932.95M |
| Current deferred revenue | 10.39M | - | - | 585.95M | - |
| Net debt | -405.39M | -31.96M | -633.22M | -272.39M | -568.53M |
| Short term debt | 191.68M | 93.22M | 139.31M | 44.92M | 43.95M |
| Short long term debt | - | 60.80M | 105.99M | 8.57M | 30.70M |
| Short long term debt total | 348.69M | 355.97M | 363.45M | 286.29M | 174.20M |
| Other stockholder equity | 616.08M | 9003.95M | 8992.45M | 9101.02M | 1206.21M |
| Property plant equipment | - | - | - | - | 182.80M |
| Total current assets | 1113.75M | 1089.91M | 1329.79M | 1246.92M | 1957.64M |
| Net tangible assets | - | - | - | - | 1136.47M |
| Short term investments | 165.08M | 285.00M | 51.85M | 483.41M | 983.62M |
| Net receivables | 33.83M | 130.88M | 172.44M | 77.13M | 117.60M |
| Long term debt | - | 257.40M | 213.00M | 218.99M | 115.81M |
| Inventory | 116.95M | 286.10M | 108.83M | 22.19M | 61.36M |
| Accounts payable | 77.24M | 338.03M | 246.38M | 290.41M | 33.02M |
| Accumulated other comprehensive income | - | 469.99M | 483.25M | - | - |
| Non currrent assets other | 0.00M | 287.62M | 2.26M | 505.17M | 1035.77M |
| Non current assets total | 245.30M | 303.56M | 332.21M | 391.51M | 313.81M |
| Capital lease obligations | - | 37.77M | 44.46M | 58.74M | 27.69M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 123.46M | -247.68M | 619.61M | 365.12M | -687.48M |
| Change to liabilities | - | - | - | 0.00M | 154.99M |
| Total cashflows from investing activities | 133.99M | -247.68M | 619.61M | - | -826.55M |
| Net borrowings | 24.20M | -0.79M | 91.43M | - | 77.72M |
| Total cash from financing activities | 577.78M | -12.90M | 388.36M | 28.47M | 92.30M |
| Change to operating activities | - | - | - | - | 88.49M |
| Net income | -423.94M | -91.21M | -367.23M | -902.68M | -1920.10M |
| Change in cash | 365.76M | -608.73M | 437.99M | -184.04M | -2281.82M |
| Begin period cash flow | 387.94M | 996.67M | 558.68M | 742.72M | 3024.55M |
| End period cash flow | 753.70M | 387.94M | 996.67M | 558.68M | 742.72M |
| Total cash from operating activities | -327.75M | -343.18M | -588.84M | -612.47M | -1484.02M |
| Issuance of capital stock | 672.46M | 0.07M | 341.82M | 2.53M | 16.83M |
| Depreciation | 43.98M | 49.80M | 58.19M | 44.54M | 22.66M |
| Other cashflows from investing activities | 10.53M | 6.46M | 171.93M | - | 10.06M |
| Change to inventory | 81.99M | -174.90M | -95.46M | 30.42M | -61.36M |
| Change to account receivables | 50.12M | 48.51M | -95.31M | - | -117.60M |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Other cashflows from financing activities | -118.89M | -12.18M | -44.90M | 57.94M | 82.18M |
| Change to netincome | - | - | - | - | 348.89M |
| Capital expenditures | 0.00M | 0.00M | 65.05M | 101.82M | 149.14M |
| Change in working capital | -75.76M | -302.80M | -139.67M | 72.65M | 64.52M |
| Stock based compensation | 23.97M | -2.81M | 36.99M | 142.06M | 222.67M |
| Other non cash items | 104.00M | 3.83M | -177.13M | 30.96M | 126.22M |
| Free cash flow | -327.75M | -343.18M | -653.89M | -714.29M | -1633.16M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CSPHF CStone Pharmaceuticals |
- -% |
0.75 | - | - | 3.42 | 7.54 | 16.33 | -0.28 |
| NVO Novo Nordisk A/S |
-1.25 3.07% |
39.45 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
536.45 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-9.75 1.02% |
948.01 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
| Name | Title | Year Born |
|---|---|---|
| Dr. Ningjun Jiang M.D., Ph.D. | Sr. Advisor | 1961 |
| Dr. Jianxin Yang M.D., Ph.D. | CEO, Sr. VP & Chief Medical Officer | 1964 |
| Mr. Jun Cheng | VP of Fin. | 1980 |
| Dr. Ngai Chiu Tse M.D., Ph.D. | Sr. VP & Chief Scientific Officer | 1967 |
| Mr. Ning He | Head of Legal Affairs & Joint Company Sec. | NA |
| Mr. Michael J. Choi M.B.A. | Chief Commercial Officer & Chief Strategy Officer | 1975 |
| Dr. - Zhou M.D. | GM of Greater China & Head of Commercial | 1981 |
| Ms. Yin Kwan Ho | Joint Company Sec. | 1977 |
| Dr. Jianxin Yang M.D., Ph.D. | CEO, President of R&D and Executive Director | 1964 |
| Ms. Weicong Ni | CFO & Joint Company Secretary | 1991 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.